Literature DB >> 9538981

Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients.

Y Tanaka1, Y Atsumi, K Matsuoka, T Onuma, T Tohjima, R Kawamori.   

Abstract

OBJECTIVE: To investigate the role of glycemic control and blood pressure in the development and progression of nephropathy and to suggest goals for glycemic control and blood pressure for the prevention of nephropathy in elderly Japanese NIDDM patients. RESEARCH DESIGN AND METHODS: A total of 123 age- and diabetes duration-matched elderly Japanese NIDDM patients (aged 60-75 years; 74 normoalbuminuric and 49 microalbuminuric) were retrospectively studied for 6 years.
RESULTS: The group that developed microalbuminuria from normoalbuminuria (group NM: n = 24) showed a higher 6-year mean HbA1c than the group that remained normoalbuminuric (group NN: n = 50; 9.0 +/- 0.8 vs. 8.1 +/- 0.8%, P < 0.01) in spite of no significant difference in 6-year mean blood pressure (MBP). On the other hand, the group that progressed from microalbuminuria to overt proteinuria (group MP: n = 26) showed a higher 6-year MBP than the group that remained microalbuminuric (group MM: n = 23; 106 +/- 5 vs. 95 +/- 6 mmHg, P < 0.01) in spite of no significant difference in 6-year mean HbA1c. The cutoff level of HbA1c separating group NN from group NM was 8.5% (normal range < or = 6.5%), and that of MBP separating group MM from group MP was 100 mmHg.
CONCLUSIONS: Glycemic control is a more potent factor than blood pressure level on the development of microalbuminuria. However, as far as the progression of microalbuminuria to overt proteinuria is concerned, hypertension is the most crucial factor in elderly NIDDM patients. Suggested goals for glycemic control and blood pressure level for the prevention of nephropathy in elderly Japanese patients are an HbA1c of < or = 8.5% (equivalent to 7.8% in the current measurement of stable HbA1c; normal range < or = 5.8%) and an MBP of < or = 100 mmHg.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9538981     DOI: 10.2337/diacare.21.1.116

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  Complications of diabetes: renal disease and promotion of self-management.

Authors:  A Melville; R Richardson; D Lister-Sharp; A McIntosh
Journal:  Qual Health Care       Date:  2000-12

3.  Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes.

Authors:  M B Davidson; D L Schriger; A L Peters; B Lorber
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

4.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

5.  Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus.

Authors:  Stanley H Hsia; Maria D Navar; Petra Duran; Magda Shaheen; Mayer B Davidson
Journal:  Endocr Pract       Date:  2011 Sep-Oct       Impact factor: 3.443

Review 6.  Antihypertensive drugs and diabetic nephropathy.

Authors:  P S Mehler; R W Schrier
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 7.  Blood pressure lowering for the prevention and treatment of diabetic kidney disease.

Authors:  Merlin C Thomas; Robert C Atkins
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  HbA1c and survival in maintenance hemodialysis patients with diabetes in Han Chinese population.

Authors:  Xiurong Li; Xianlin Xu; Jinfeng Liu; Junwei Yang; Li Fang; Liying Miao; Jia Di; Xiaozhou He
Journal:  Int Urol Nephrol       Date:  2014-06-26       Impact factor: 2.370

9.  Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs.

Authors:  Laura A Maile; Walker H Busby; Katherine A Gollahon; William Flowers; Nikol Garbacik; Stefani Garbacik; Kara Stewart; Timothy Nichols; Dwight Bellinger; Amit Patel; Paul Dunbar; Matt Medlin; David Clemmons
Journal:  Endocrinology       Date:  2014-08-29       Impact factor: 4.736

Review 10.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.

Authors:  Merlin C Thomas; Mark E Cooper; Paul Zimmet
Journal:  Nat Rev Nephrol       Date:  2015-11-10       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.